Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Homologous Recombination02:31

Homologous Recombination

50.2K
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
50.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Tumors.

Cancer research·2024
Same author

Author Correction: poly(UG)-tailed RNAs in genome protection and epigenetic inheritance.

Nature·2021
Same author

Targeting translesion synthesis (TLS) to expose replication gaps, a unique cancer vulnerability.

Expert opinion on therapeutic targets·2021
Same author

Replication Gaps Underlie BRCA Deficiency and Therapy Response.

Cancer research·2020
Same author

Inhibition of the translesion synthesis polymerase REV1 exploits replication gaps as a cancer vulnerability.

Science advances·2020
Same author

poly(UG)-tailed RNAs in genome protection and epigenetic inheritance.

Nature·2020

Related Experiment Video

Updated: Jun 8, 2025

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

14.6K

Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines.

Anne E Dodson1, Sol Shenker1, Pamela Sullivan1

  • 1KSQ Therapeutics, Lexington, Massachusetts.

Cancer Research Communications
|November 1, 2024
PubMed
Summary

Homologous recombination deficiency (HRD) is a key factor in cancer genomic instability. This study validated HRD prediction methods in over 1,300 cell lines, revealing associations with genetic dependencies and drug sensitivity.

More Related Videos

Author Spotlight: Decoding DNA Repair by Extrachromosomal NHEJ Assay and HR Assays
09:29

Author Spotlight: Decoding DNA Repair by Extrachromosomal NHEJ Assay and HR Assays

Published on: February 2, 2024

1.9K
Visualization of DNA Repair Proteins Interaction by Immunofluorescence
07:55

Visualization of DNA Repair Proteins Interaction by Immunofluorescence

Published on: June 26, 2020

10.1K

Related Experiment Videos

Last Updated: Jun 8, 2025

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

14.6K
Author Spotlight: Decoding DNA Repair by Extrachromosomal NHEJ Assay and HR Assays
09:29

Author Spotlight: Decoding DNA Repair by Extrachromosomal NHEJ Assay and HR Assays

Published on: February 2, 2024

1.9K
Visualization of DNA Repair Proteins Interaction by Immunofluorescence
07:55

Visualization of DNA Repair Proteins Interaction by Immunofluorescence

Published on: June 26, 2020

10.1K

Area of Science:

  • Oncology
  • Genomics
  • Cancer Biology

Background:

  • Homologous recombination deficiency (HRD) is crucial for genomic instability and cancer vulnerability to DNA-damaging agents like PARP inhibitors.
  • HRD is an emerging biomarker in oncology, but comprehensive analysis in cell lines is limited.

Purpose of the Study:

  • To comprehensively predict HRD in a large panel of cancer cell lines using established in silico methods.
  • To validate HRD prediction tools and explore the genomic and drug sensitivity profiles associated with HRD in cell lines.

Main Methods:

  • Utilized "Classifier of HOmologous Recombination Deficiency" and "HRDsum" scores to predict HRD in 1,332 cancer and 84 noncancerous cell lines.
  • Validated prediction methods using cell lines with known BRCA1/2 mutations.
  • Analyzed associations between HRD and p53 loss, microsatellite instability, cancer types, genetic dependencies, and drug sensitivity.

Main Results:

  • The two HRD prediction methods successfully identified cell lines with biallelic BRCA1/2 mutations.
  • HRD was associated with p53 loss, mutually exclusive with microsatellite instability, and frequent in breast and ovarian cancers.
  • HRD in cell lines correlated with PARP inhibitor sensitivity in breast cancer, but not pan-cancer.

Conclusions:

  • Validated in silico HRD prediction methods in a large cell line dataset.
  • Identified novel associations between HRD and genetic/drug sensitivity profiles, particularly PARP inhibitor sensitivity in breast cancer cell lines.
  • Generated a valuable pan-cancer HRD dataset to advance HRD biomarker research.